Skip to main content

Drug manufacturer Catalent’s stock tumbles 25% after profit warning and CFO departure

Drug manufacturer Catalent said higher-than-expected costs and productivity issues at three plants would have a material adverse impact on fiscal third-quarter earnings.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.